Navigation Links
Cetero Research Announces Executive Appointments and New Company Name
Date:6/20/2012

CARY, N.C., June 20, 2012 /PRNewswire/ -- Cetero Research announced the completion of a major milestone in its reorganization efforts. Following the company filing for reorganization under Chapter 11 and the U.S. District Bankruptcy Court's approval of the sale of Cetero to its investor group, led by Freeport Financial, the sale of the company was finalized on June 20, 2012.

(Photo: http://photos.prnewswire.com/prnh/20120620/PH27754 )

Over recent months, Cetero has engaged with lenders and stakeholders to plan a growth-filled future for the company. As a first step in this process, the board of directors has named three executive appointments to lead operational, financial and new business initiatives.

James Carlson, Pharm.D, has been named Chief Executive Officer, based on his extensive background in the Phase I research space and reputation for entrepreneurial leadership. Dr. Carlson is a life science industry veteran with more than 30 years of experience in early phase research. He co-founded and served as CEO of a legacy operation of Cetero Research, based in Fargo, ND, from 1983 to 2006, where he oversaw the conduct of more than 450 studies per year across a wide range of therapeutic indications and study types. A 250,000 square-foot clinical pharmacology unit with specialization in cardiac safety and healthy participants for bioavailability, bioequivalence, preclinical and clinical dermatology studies, this facility is the largest Phase I unit in the world.  As part of the new ownership structure, the company's headquarters will move from Cary, NC, to Fargo, ND, and the company has been renamed PRACS Institute.

Mark Ubert, CPA, MBA, has been named Chief Financial Officer. Mr. Ubert joined Cetero in 2009 as corporate controller, bringing extensive experience in financial leadership, corporate treasury, mergers and acquisitions, accounting and operational performance improvement within the life science and healthcare industries. In his new position, Mr. Ubert is responsible for the overall financial operations of the company, including corporate finance, treasury, financial planning and analysis, tax, accounting internal audit and risk management.

John Pottier has been named Executive Vice President, Business Development. With more than 20 years of industry experience, Mr. Pottier brings significant expertise in early phase clinical knowledge and R&D business requirements. Joining PRACS from Worldwide Clinical Trials, Mr. Pottier previously served in business development roles at Novum Research, Cetero Research and PRACS Institute, Ltd., after beginning his career at the Clinical Research Foundation, now part of Quintiles Transnational.

"This is an exciting time for our new company. We have a lot of work ahead of us, and we look forward to strengthening our organization and integrating service offerings," said Dr. Carlson. "We will continue to uphold the company's commitment to the delivery of reliable, quality data and on-time study results, as well as the safety of our study participants," he added.

As biopharmaceutical companies seek new ways to help manage drug costs and navigate the rising complexity of early phase development, sponsors are starting to rely more heavily on niche providers like PRACS, who is well positioned to serve the generic, innovator and dermatology markets.  PRACS has the flexibility and capacity to accommodate the expected increase of bioavailability and bioequivalence studies following near-term patent expirations. 

About PRACS Institute

A leading early-phase contract research organization, PRACS has conducted more than 20,000 clinical pharmacology studies more than any other CRO. With facilities across North America, PRACS offers flexible, quality clinical development services in a range of therapeutic areas.  For more information, visit PRACS.com.

About Freeport Financial

Founded in 2004 by a group of experienced corporate finance and capital markets professionals, Freeport Financial is a leading provider of capital and leveraged finance solutions to middle market companies.  


'/>"/>
SOURCE PRACS Institute
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... 27, 2017  Kinexum, a distinguished resource for research, ... the appointment of Thomas C. Seoh as ... M.D., Kinexum founder, who becomes Executive Chairman and will ... clients. Thomas Seoh commented, "I ... mission and lead the firm,s remarkable team of life ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December ... its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) ... to offer NAT screening for blood donors under an Investigational New Drug (IND) study ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... R.I. , April 25, 2017 ... Inc. ("EpiVax") has licensed its novel immune-modulating technology to ... autoimmune disease and allergy. Tregitopes, pronounced ... in human immunoglobulin by EpiVax CEO Annie ... Similar to intravenous immunoglobulin G, an autoimmune disease ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):